Messaging Around Clinical Data

A specialty pharmaceuticals company that was already a Westwicke Partners client expected an FDA decision regarding approval of a new product that had the potential to achieve peak annual sales which could exceed anything in its current product line by at least three times.

A public specialty pharmaceutical company was preparing for the release of crucial Phase 3 clinical data. There were several nuances to the data, and it was crucial to the company’s capital markets and investor relations strategy that the data be appropriately understood by Wall Street.